Evaluation of Safety and Systemic Pharmacokinetics After Abicipar Pegol (AGN-150998) Intravitreal Injections in Japanese Patients With NEovascular Age-Related Macular Degeneration (PINE Study)
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2018
Price : $35 *
At a glance
- Drugs Abicipar pegol (Primary)
- Indications Age-related macular degeneration
- Focus Pharmacokinetics
- Acronyms PINE Study
- Sponsors Allergan
- 31 Oct 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 23 May 2018 Status changed from recruiting to active, no longer recruiting.